Biased Ligands. Better Drugs.

Press Releases

Recent News

June 28, 2018 Trevena announces successful completion of Phase 1 study of TRV250 for acute migraine

June 11, 2018 Trevena Expands Commercial and Medical Affairs Leadership Teams with Key Hires

May 30, 2018 Trevena to Present at the Jefferies Global Healthcare Conference

May 22, 2018 Trevena announces presentations at the American Society of Colon and Rectal Surgeons 2018 Annual Scientific Meeting

May 21, 2018 Trevena Appoints Mark A. Demitrack, M.D., as Chief Medical Officer

May 8, 2018 Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 3, 2018 Trevena Reports First Quarter 2018 Financial Results

May 2, 2018 Trevena to Present at the Deutsche Bank 43rd Annual Healthcare Conference

May 1, 2018 Trevena Inc. and Jiangsu Nhwa Pharmaceutical Co. Ltd Announce License Agreement for Oliceridine in China

April 27, 2018 Trevena and Pharmbio Korea Announce License and Commercialization Agreement for Oliceridine in South Korea

April 26, 2018 Trevena to Report First Quarter 2018 Financial Results on May 3, 2018

April 5, 2018 Trevena Announces Retirement of Maxine Gowen, Ph.D., Effective October 1, and Planned Promotion of Carrie L. Bourdow to President and Chief Executive Officer

March 20, 2018 Trevena to Present at the Needham & Company 17th Annual Healthcare Conference

March 14, 2018 Trevena to Present at the Oppenheimer & Company 28th Annual Healthcare Conference

March 7, 2018 Trevena to Present at the Cowen and Company 38th Annual Healthcare Conference

March 7, 2018 Trevena Reports Full Year 2017 Earnings

March 2, 2018 Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 28, 2018 Trevena to Host Conference Call on March 7th to Discuss Full Year 2017 Financial Results

February 2, 2018 Trevena Promotes Carrie Bourdow to Executive Vice President and Chief Operating Officer

January 2, 2018 Trevena Announces FDA Acceptance for Review of New Drug Application for Oliceridine Injection

Copyright © Trevena, Inc.